Melanotan I and II Explained: Tanning, MC1R, MC4R, and the Melanocortin System

Scientific concepts / biological mechanisms described

1) UV damage → tanning signaling cascade (natural tanning biology)

• Primary UV effect: UV-induced DNA damage in keratinocytes (epidermal structural cells).
• Damage response: DNA stress activates p53, a transcription factor that changes gene expression.
• Paracrine signaling: p53 increases POMC-pathway activity, leading keratinocytes to release α-MSH locally.
• Receptor activation on melanocytes: α-MSH diffuses to nearby melanocytes and binds melanocortin 1 receptor (MC1R).
• Intracellular amplification in melanocytes:
  • MC1R activation increases cAMP (secondary messenger)
  • activates protein kinase A (PKA) → CREB
  • increases MITF (transcription factor)
  • upregulates pigment machinery, especially tyrosinase (rate-limiting enzyme for melanin synthesis)
• Key idea: Visible tan is a downstream consequence of signaling + pigment handling, not a direct measure of safety.

2) “Injected melanotan” vs natural UV signaling

• Natural tanning is local and feedback-limited (UV → keratinocyte signaling → nearby melanocytes).
• Melanotan peptides are described as systemic receptor agonists:
  • they can bypass upstream checks (skipping UV/DNA-damage steps)
  • activate melanocortin receptors wherever the drug reaches accessible tissues
  • therefore effects and risks depend on which receptor subtypes are activated and where

3) Melanocortin system: receptor family and POMC precursor

• POMC (Proopiomelanocortin) is a common precursor expressed/processed in multiple tissues.
• POMC processing depends on tissue-specific convertases:
  • PC1/3 and PC2 (prohormone convertases)
• Branches include:
  • ACT (via PC1/3 processing) → adrenal stimulation of cortisol (stress axis)
  • MSH peptides, including α-MSH, β-MSH, γ-MSH
• Shared concept: melanocortins act through receptor-binding motifs, linking pigment signaling to stress/appetite pathways.

4) MC1R genetics and tanning variability

• MC1R is polymorphic: common gene variants can produce reduced-function receptors.
• Result: similar α-MSH exposure can yield different tanning/pigment responses across genotypes.
• Limiting factor is described as receptor responsiveness, not only receptor quantity.

5) Melanin types and photoprotection

• Melanocytes produce two main pigment classes:
  • Eumelanin (brown–black; stronger UV/visible photoprotection)
  • Pheomelanin (red–yellow; weaker UV shielding and may contribute more to oxidative stress)
• MC1R signaling is described as biasing production toward eumelanin, changing:
  • amount of pigment
  • ratio/type of eumelanin vs pheomelanin

6) How tan pigment is physically formed (cellular packaging)

• Melanin is not “free-floating”; it is packaged into melanosomes.
• Melanocytes transfer melanosomes via dendritic extensions to keratinocytes.
• In keratinocytes, pigment clusters form super-nuclear caps (above the nucleus), contributing to:
  • visible tan
  • DNA shielding

---

Methodology / study-evidence structure mentioned

Evidence for afamelanotide (Melanotan 1; brand described as Scenesse)

• Indication context: treated for erythropoietic protoporphyria (EPP) (photosensitivity with painful light exposure).
• Evidence described as controlled trials using implants:
  • participants receive active implants vs vehicle (placebo-like matrix) implants
  • blinding: participants and investigators do not know assignment
  • primary outcome: increased time in direct midday sun without pain
• Reported outcomes (as described):
  • main vehicle-controlled trial: ~64 hours pain-free with active vs 40 hours with vehicle over ~180 days
  • additional/secondary follow-up trial(s) described as strengthening results (including one later trial with a more favorable p-value and one trial that missed a prespecified endpoint)
• Safety monitoring: adverse events (e.g., implant site reactions and nausea) were prospectively recorded and compared to vehicle.

Evidence for melanotan 2

• Evidence base described as weaker in cosmetics:
  • unapproved
  • dosing varies widely (no regulated schedule), complicating interpretation of case reports

Evidence for non-skin effects (mechanistic + case reports)

• Mechanism tied to melanocortin receptor pharmacology:
  • MC4R: appetite/energy balance and autonomic effects in brain pathways
  • MC1R: skin pigment
• Claims about cardiovascular/neurologic events are described as:
  • plausible mechanism + warnings/label evidence from regulated analogs + case reports in melanotan users
  • but causality cannot be definitively proven from case reports

---

Scientific discoveries / key pharmacology points described

1) Receptor subtype targeting and different risk profiles

• Melanocortin receptors are treated as a family of distinct “switches”:
  • MC1R (pigment, skin)
  • MC4R (appetite, autonomic circuits)
  • MC2R (adrenal cortisol axis via ACT)
  • MC3R / MC5R also implicated in additional systemic effects
• Therefore, different melanocortin agonists can have substantially different effects and risk, even if they overlap receptor activation.

2) Afamelanotide (Melanotan 1 / Scenesse) described mechanism

• A synthetic α-MSH analog designed to resemble α-MSH.
• Described features:
  • more stable peptide via amino-acid substitutions → longer duration
  • increases MC1R-driven eumelanin in upper epidermis in EPP
• Not a “sunblock”: it raises the pain threshold rather than permanently correcting the underlying enzyme defect.

3) Melanotan 2 described pharmacology

• Described as:
  • cyclic, slowing breakdown
  • non-selective across multiple melanocortin receptors: MC1R, MC3R, MC4R, MC5R (with little MC2R activity noted)
• Expected downstream effects (mechanistic):
  • pigmentation (MC1R)
  • appetite suppression and autonomic effects (MC4R)
  • sexual function/autonomic changes (MC4R-linked circuits)
  • sweating/acne/oily skin (MC5R on exocrine glands)
• Lack of approved dosing standard increases uncertainty in adverse-event interpretation.

4) Bremelanotide (viL) described as an MC4R-focused clinical example

• FDA-approved for acquired generalized hypoactive sexual desire disorder in premenopausal women (per subtitle description).
• Labeled as non-selective, but described as MC4R therapeutically relevant.
• Label-driven warnings include:
  • skin hyperpigmentation
  • changes to nevi (moles)
  • cardiovascular and other monitored effects
• Used to illustrate that even more receptor-focused drugs can still produce pigment-related effects via residual MC1R activity.

---

Safety concerns and uncertainties highlighted

1) Melanoma risk discussion is mechanistically plausible but not proven

• Concern: MC1R activation increases pigment/melanocyte activity, and melanoma arises from melanocytes.
• Evidence basis described:
  • case reports of changing moles and melanoma after melanotan use
  • no definitive incidence rates (cosmetic users are not tracked)
• Distinction emphasized:
  • case reports establish temporality, not causation
  • strong confounding likely (notably sunbed use / UV exposure and baseline susceptibility)

2) Mole (nevi) changes complicate detection

• Melanotan could cause rapid mole darkening/growth, making it harder to:
  • perform dermoscopic differentiation
  • detect clinically suspicious lesions among many changing lesions

3) Cardiovascular and neurologic risk signals (case reports + mechanism)

• Suggested links:
  • MC4R-driven autonomic effects can change blood pressure and heart rate
  • a case report described renal infarction (CT evidence of occluded renal artery)
  • another neurologic syndrome mentioned: posterior reversible encephalopathy syndrome (PRES) associated with acute blood pressure elevation

4) Specific adverse events described and mechanistic mapping

• Priapism (erection lasting > ~4 hours) described as a medical emergency; reported after melanotan 2 injections (case-level evidence)
• Nausea and other autonomic symptoms (flushing, yawning, sweating) described as consistent with melanocortin receptor activation outside skin (especially MC4R-linked circuits)
• Sweating/oily skin/acne described as consistent with MC5R activity at glands
• Rhabdomyolysis: muscle breakdown reported in a case with severe labs and acute kidney injury; interpretation limited by confounders (e.g., possible overdose level and positive opioid screen)

5) Long-term unknowns

• No robust long-term outcomes data for cosmetic melanotan use.
• Concern that harm might appear years later (e.g., cancer risk, cardiovascular sequelae)

---

Researchers or sources featured (as named in the subtitles)

• p53 (described as a transcription factor; no specific researcher named)
• Leptin (hormone referenced; no researcher named)
• MITF, CREB, tyrosinase, POMC, PC1/3, PC2, ACT, α-MSH, α-MSH/MC1R/MC4R/MC2R/MC5R (molecules/receptors referenced; no individual researchers credited)
• No specific individual researchers, institutions, or journal authors are explicitly named in the provided subtitles.